

Identify Drug Milestones in Cortellis

This guide explains where to find upcoming and achieved milestones for the development of a drug of interest.

‘Milestones’ in drug reports provide details of important past events in the drug history and dates when news is expected from clinical trials, regulatory designations and registration. This information will help you identify any delays or early news on clinical trial results, approval process and more.

Example: Identify when clinical trial results are expected for *supalutai*.

1. Quick search the drug name at the top and select ‘**Index**’.



2. Click the **drug name** in the results table.

Results

Per page: 25

Sort by: Relevance

Order Columns

View

Drug Name	Active Companies	Active Indications	Target-based Actions	Highest Status	Technologies
	Filters : [0]	Filters : [0]	Filters : [0]	Filters : [0]	Filters : [0]
supalutai	Hongkong Invengen Pharmaceutical Technology Co Ltd; Kunming Pharmaceutical Corp	Non-insulin dependent diabetes	Glucagon-like peptide 1 receptor agonist; Immunoglobulin gamma Fc receptor agonist	Phase 3 Clinical	Biological therapeutic; Immunoglobulin G isotype antibody; Protein fusion; Subcutaneous formulation; Sustained release formulation

3. Go to ‘**Milestones**’ tab.

supalutai

Snapshot	Highlight <input type="checkbox"/> Search Terms & Synonyms	< Previous	Next >					
Latest Press Releases	DRUG MILESTONES							
Latest Event Transcripts	Date	Milestone	Category	Indication	Company	Country/Territory	Status	Description
Broker Research Reports	28-Aug-2023	Expected Trial End Date	Clinical	Non-insulin dependent diabetes	Kunming Pharmaceutical Corp	China	Planned	In July 2021, a phase III trial (NCT04998032) was planned in China for type 2 diabetes suboptimally controlled on metformin. At that time, the trial was planned to complete in August 2023 [2509424].
Development Profile	28-Aug-2023	Expected Trial End Date	Clinical	Non-insulin dependent diabetes	Hongkong Invengen Pharmaceutical Technology Co Ltd	China	Planned	In July 2021, a phase III trial (NCT04998032) was planned in China for type 2 diabetes suboptimally controlled on metformin. At that time, the trial was planned to complete in August 2023 [2509424].
Literature Review								
Development Status								
Regulatory Designations								
Milestones								

As of July 2021, clinical trial results were expected for *supalutai* in Aug 2023. You can navigate to this drug report by clicking [this link](#).

4. Filtering and sorting options at the top allow you to narrow down and rank the table according to your interest. For example, click '**IND Filing**' under '**Milestone**' to retrieve date, indication, country and status of different IND applications.

Date, indication, company, country and status are provided for each milestone with a summary and link(s) to the source.

DRUG MILESTONES

Date	Milestone	Category	Indication	Company	Country/ Territory	Status	Description
21-Jul-2023	IND Filing	Registration	Non-insulin dependent diabetes	Shanghai Innogen Pharmaceutical Technology Co, Ltd	China	Filed	In July 2023, another IND application was filed in China [2996061].
16-May-2023	IND Filing	Registration	Non-insulin dependent diabetes	Shanghai Innogen Pharmaceutical Technology Co, Ltd	China	Filed	In May 2023, another IND application was filed in China [2920761].
14-Jun-2018	IND Filing	Registration	Non-insulin dependent diabetes	Kunming Pharmaceutical Corp	China	Granted	In June 2018, a clinical trial approval was obtained for in China [2183142].

Sort

☒ Ascending
 ☒ Descending

Filter

☐ Select All
☐ Expected Trial End Date
☐ Expected Trial Start Date
☒ **IND Filing**
☐ Interim Trial Results Published
☐ Predicted Launch Date
☐ Trial Endpoints Met
☐ Trial Top line Results Published

To find out what's included in your subscription, contact your Clarivate account manager or **[LS Product Support](#)**.